Carterra 23/09/25
LB Bohle – 10.06.2025
Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Pharmapack 2026
SAE Media – pre-filled syringes EU 19/11/25
Terumo 05/01
SAE Media – pre-filled syringes – East Coast 19/11/25
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025

Electronic Manufacturing Batch Records and Digitalisation in Biopharmaceutical Manufacturing

In response to the evolving expectations of the biopharmaceutical industry, contract manufacturing organisations (CMOs) are facing mounting pressure to optimise processes, uphold data integrity, and scale operations. Traditional paperbased manufacturing batch record (pMBR) practices have become barriers to agility. They limit process visibility, introduce transcription and review errors, and generate bottlenecks that can delay batch release and delivery.

The growing regulatory requirements for ALCOA++ principles, quality, and safety have pushed the industry to transition from paperbased to digitalised record systems, known as electronic batch records, often referred to as electronic manufacturing batch records (eMBRs). Through eMBRs, biomanufacturers can secure data traceability, achieve realtime process oversight, and enable faster, more reliable operations. However, the digital transition has faced roadblocks due to the lack of systematic know-how and expertise.

eMBR systems electronically manage data flow related to operations on the production floor. Unlike paper records that require human transcription, eMBRs interface with various data platforms – enterprise resource planning systems, laboratory information management systems (LIMS), manufacturing execution systems (MES), equipment control systems (distributed control system or individual programmable logic controller), and quality management systems. This interconnectivity enables real-time data flow across business, manufacturing, and quality operations.

Critically, eMBRs support the execution of manufacturing processes step by step through validated, standardised templates. They reinforce procedural adherence, eliminate transcription mistakes, enable immediate access to records, and address key vulnerabilities of paper-based systems. By safeguarding record integrity and providing a robust audit trail, eMBRs generate trustworthy data that meet the expectations of global authorities, such as the U.S. Food and Drug Administration and European Medicines Agency.

Challenges in Traditional Batch Record Management

Historically, pMBR has relied on manual document preparation, change management, and data entry. Operators consult multiple external systems, write down process information on paper, and later transfer the data to other systems. All activities are cross verified, then reviewed by the quality team to ensure integrity. These procedures are timeintensive, error-prone, and dependent on human vigilance.

Nipro – 07/01/2026
YPSOMED website ad
Scott Pharma – 25.03.2025
Bespak – 21.05.2025
SAE Media – AI in DD
HCMed
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
Aptar – 08/01/2026
Nipro – 09.06.2025
Stoelzle – 15th May 2025
L.B. Bohle – 08.04.2025